FindTrial
Sign In

Randomized Controlled Double-Blind-Study of Role of Recombinant Erythropoietin in the Prevention of Chronic Lung-Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN90717641
Enrollment
Unknown
Registered
2004-01-23
Start date
1993-06-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal diseases Neonatal Diseases

Interventions

Infants were randomly allocated and received either R-HuEpo (480 U/kg/wk) or placebo (4% human serum albumin) by twice weekly subcutaneous injection.

Sponsors

NHS R&D Regional Programme Register - Department of Health (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Gestational age <32 weeks and/or birthweight <1500 g 2. Requirement for mechanical ventilation and/or supplemental oxygen at birth 3. No severe renal, hepatic or coagulation disorders or major congenital malformation 4. Still require mechanical ventilation/oxygen on day 7-14 after birth

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Secondary

MeasureTime frame
Number of blood transfusions required—

Primary

MeasureTime frame
Number of days on respiratory support—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026